More than half of patients alive two years after receiving CART therapy for diffuse large Bcell lymphoma in ZUMA1 trial

More than half of patients alive two years after receiving CAR-T therapy for diffuse large B-cell lymphoma in ZUMA-1 trial

(University of Texas M. D. Anderson Cancer Center) A follow-up analysis of patients enrolled in a Phase I/II multi-center trial for diffuse large B-cell lymphoma (DLBCL) reported 51 percent of patients receiving an anti-CD19 chimeric antigen receptor (CAR T) called axi-cel were still alive two years post-treatment.

More From BioPortfolio on "More than half of patients alive two years after receiving CAR-T therapy for diffuse large B-cell lymphoma in ZUMA-1 trial"